Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Guthrie

Showing results (111-120 of 112) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 112 results.
Npj Drug Discovery|July 1, 2026
The antibody-peptide fusion protein, AT-02, is an effective opsonin with pan-amyloid reactivityJ S Wall, A D Williams, M Balachandran, et al.
European Journal of Neurology|April 29, 2020
Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trialT H Brannagan, A K Wang, T Coelho, et al.
Pageof 12

Showing results (111-120 of 112) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 112 results.
Npj Drug Discovery|July 1, 2026
The antibody-peptide fusion protein, AT-02, is an effective opsonin with pan-amyloid reactivityJ S Wall, A D Williams, M Balachandran, et al.
European Journal of Neurology|April 29, 2020
Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trialT H Brannagan, A K Wang, T Coelho, et al.
Pageof 12